Viral rebound uncommon after molnupiravir, nirmatrelvir-ritonavir therapy
Patients with COVID-19 taking molnupiravir or nirmatrelvir-ritonavir rarely have viral rebound, and rebound is not associated with increased mortality risk, according to a study published online Dec. 6 in JAMA Network Open.
Dec 9, 2022
0
4